Key facts
- This page summarizes Marc Lustig's Form 4 filing for BriaCell Therapeutics Corp. (BCTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 May 2024, 16:00.
Marc Lustig - 14 May 2024 Form 4 Insider Report for BriaCell Therapeutics Corp. (BCTX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- BCTX
- Reported as of
- 14 May 2024
- Net transaction value
- +$2,000,001
- SEC form
- 4
- Accepted by SEC
- 20 May 2024, 16:00:14 UTC
- Prior SEC filing
- 02 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc Lustig
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Marc Lustig filed Form 4 for BriaCell Therapeutics Corp. (BCTX) on 20 May 2024.
Change
- Previous filing in this sequence was filed on 02 Aug 2022.
- Current net transaction value: +$2,000,001.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCTX
transaction
Common Shares
Purchase
- Transaction value
- $2,000,001
- Shares
- +902,935
- Change %
- +55%
- Price
- $2.22
- Shares after
- 2,542,935
- Date
- 14 May 2024
- Ownership
- By L5 Capital Inc.
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCTX
transaction
Derivative
Common Stock Warrants
Purchase
- Transaction value
- Shares
- +902,935
- Change %
- Price
- Shares after
- 902,935
- Date
- 14 May 2024
- Ownership
- By L5 Capital Inc.
- Underlying class
- Common Stock
- Underlying amount
- 902,935
- Exercise price
- $2.11
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.